Holen Sie sich die Stockscreener-App
16.36
1.72%
-0.295
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$16.65
Offen:
$16.66
24-Stunden-Volumen:
5.25M
Relative Volume:
0.47
Marktkapitalisierung:
$19.04B
Einnahmen:
$14.57B
Nettoeinkommen (Verlust:
$-296.50M
KGV:
-63.15
EPS:
-0.259
Netto-Cashflow:
$1.64B
1W Leistung:
+1.19%
1M Leistung:
+12.15%
6M Leistung:
+53.79%
1J Leistung:
+97.38%
1-Tages-Spanne:
$16.27
$16.76
1-Wochen-Bereich:
$16.20
$16.76
52-Wochen-Spanne:
$8.32
$17.53
Viatris Inc Stock (VTRS) Company Profile
Firmenname
Viatris Inc
Sektor
Telefon
(724) 514-1465
Adresse
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
16.35 | 19.39B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.26 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.74 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.81 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.01 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Hochstufung | UBS | Neutral → Buy |
| 2026-01-16 | Hochstufung | Argus | Hold → Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-06-06 | Eingeleitet | Goldman | Neutral |
| 2024-07-19 | Fortgesetzt | Jefferies | Buy |
| 2023-10-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-10 | Hochstufung | UBS | Sell → Neutral |
| 2022-11-08 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Fortgesetzt | Jefferies | Hold |
| 2022-06-14 | Eingeleitet | UBS | Sell |
| 2022-05-10 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Eingeleitet | Citigroup | Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Eingeleitet | Argus | Hold |
| 2020-12-14 | Eingeleitet | Bernstein | Mkt Perform |
Alle ansehen
Viatris Inc Aktie (VTRS) Neueste Nachrichten
Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035 - GlobeNewswire Inc.
Viatris Inc. (VTRS) Stock Analysis: Investor Outlook on a Healthcare Giant with an 8.44% Upside Potential - DirectorsTalk Interviews
Assessing Viatris (VTRS) Valuation After FDA Review Acceptance For Fast Acting Non Opioid Meloxicam - Yahoo Finance
FDA accepts Viatris' NDA for fast-acting non-opioid pain therapy - MSN
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
VTRS News | VIATRIS INC (NASDAQ:VTRS) - ChartMill
What Viatris (VTRS)'s Fast-Acting Pain Drug Filing and Profit Uptick Means For Shareholders - simplywall.st
Viatris Inc.: - marketscreener.com
Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Viatris (VTRS) price target increased by 10.47% to 17.48 - MSN
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
VTRS Technical Analysis | Trend, Signals & Chart Patterns | VIATRIS INC (NASDAQ:VTRS) - ChartMill
VTRS Maintains Overweight Rating -- Price Target Raised to $22 - GuruFocus
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy - Yahoo Finance
Viatris CFO leaving Canonsburg pharma giant - MSN
Barclays Adjusts Price Target on Viatris to $22 From $17, Maintains Overweight Rating - Moomoo
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain - Sahm
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Me - GuruFocus
TrumpRx expands into generic medicines (VTRS:NASDAQ) - Seeking Alpha
Viatris rises as Q1 beat indicates growth momentum - MSN
Viatris' Acute Pain Drug NDA Accepted for Review by FDA - Moomoo
5 Revealing Analyst Questions From Viatris’s Q1 Earnings Call - Yahoo Finance
Here's Why Viatris (VTRS) is a Strong Momentum Stock - Yahoo Finance
U.S. FDA accepts Viatris new drug application for fast-acting meloxicam for the treatment of moderate-to-severe acute pain - marketscreener.com
U.S. FDA Accepts Viatris New Drug Application For Fast-Acting Meloxicam For The Treatment Of Moderate-To-Severe Acute Pain - TradingView
Small Cap Opportunities Trust's Viatris Inc(VTRS) Holding History - GuruFocus
FDA accepts Viatris application for fast-acting meloxicam By Investing.com - Investing.com Nigeria
FDA accepts Viatris application for fast-acting meloxicam - Investing.com
Viatris Inc. (VTRS) Stock Analysis: Exploring a 6.19% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Viatris Inc.Common Stock (NQ: VTRS - FinancialContent
Shareholders that lost money on Viatris Inc.(VTRS) should contac - GuruFocus
Viatris Shareholders Approve Directors, Pay and Auditor - The Globe and Mail
Understanding Momentum Shifts in (VTRS) - Stock Traders Daily
Viatris Inc (VTRS) Stock Down 4.5% but Still Overvalued -- GF Sc - GuruFocus
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Viatris (VTRS) investors elect full board and approve 2025 pay, auditor - Stock Titan
Does Strong Q1 Results And CFO Transition Change The Bull Case For Viatris (VTRS)? - Yahoo Finance
Bacterial Vaginosis Drug Market Will Generate Booming Growth - openPR.com
Biosimilars Market is expected to Hit US$ 99.3 Billion by 2033 | - openPR.com
Fed. Circ. Won't Save Actelion's Suit Over Hypertension Drug - Law360
Earnings call transcript: Viatris Q1 2026 beats EPS forecast, stock rises - Investing.com
Earnings call transcript: Viatris Q1 2026 beats EPS forecast, stock rises By Investing.com - Investing.com South Africa
Viatris Hypertension Drug Doesn’t Copy J&J Patents, Court Says - Bloomberg Law News
Why Viatris (VTRS) is a Top Value Stock for the Long-Term - sharewise.com
HHS officials considered banning SSRI antidepressantsreport - MSN
Viatris (VTRS) Is Up 10.6% After Q1 Beat, CFO Change And Outlook ReaffirmationWhat's Changed - simplywall.st
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Transcript : Viatris Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 08 - marketscreener.com
Why Viatris (VTRS) is a Top Growth Stock for the Long-Term - Yahoo Finance
Finanzdaten der Viatris Inc-Aktie (VTRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):